CO2024006727A2 - Compuestos y composiciones macrocíclicos, y métodos para preparar y utilizar los mismos - Google Patents
Compuestos y composiciones macrocíclicos, y métodos para preparar y utilizar los mismosInfo
- Publication number
- CO2024006727A2 CO2024006727A2 CONC2024/0006727A CO2024006727A CO2024006727A2 CO 2024006727 A2 CO2024006727 A2 CO 2024006727A2 CO 2024006727 A CO2024006727 A CO 2024006727A CO 2024006727 A2 CO2024006727 A2 CO 2024006727A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- same
- preparing
- compositions
- macrocyclic compounds
- Prior art date
Links
- 150000002678 macrocyclic compounds Chemical class 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 108091005640 farnesylated proteins Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a compuestos macrocíclicos de una cualquiera de la fórmula (I), o una forma farmacéuticamente aceptable de estos, composiciones farmacéuticas que comprenden los mismos, métodos para preparar los mismos, y métodos para tratar el cáncer dependiente de una proteína farnesilada, utilizando los mismos.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111442658 | 2021-11-30 | ||
US202163285412P | 2021-12-02 | 2021-12-02 | |
CN202211471486 | 2022-11-23 | ||
US202263385117P | 2022-11-28 | 2022-11-28 | |
PCT/US2022/080565 WO2023102378A1 (en) | 2021-11-30 | 2022-11-29 | Macrocyclic compounds having farnesyltransferase inhibitory activity |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2024006727A2 true CO2024006727A2 (es) | 2024-07-18 |
Family
ID=84981542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2024/0006727A CO2024006727A2 (es) | 2021-11-30 | 2024-05-27 | Compuestos y composiciones macrocíclicos, y métodos para preparar y utilizar los mismos |
Country Status (10)
Country | Link |
---|---|
US (2) | US12018011B2 (es) |
KR (1) | KR20240110978A (es) |
AU (1) | AU2022399572A1 (es) |
CA (1) | CA3234276A1 (es) |
CO (1) | CO2024006727A2 (es) |
DO (1) | DOP2024000102A (es) |
IL (1) | IL312132A (es) |
MX (1) | MX2024005822A (es) |
TW (1) | TW202327590A (es) |
WO (1) | WO2023102378A1 (es) |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
AU6242096A (en) | 1995-06-27 | 1997-01-30 | Takeda Chemical Industries Ltd. | Method of producing sustained-release preparation |
TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
EP1162201B1 (en) * | 1995-12-08 | 2006-03-29 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives |
US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
ES2221019T3 (es) | 1996-10-31 | 2004-12-16 | Takeda Chemical Industries, Ltd. | Preparacion de liberacion mantenida. |
ZA9711385B (en) | 1996-12-20 | 1999-06-18 | Takeda Chemical Industries Ltd | Method of producing a sustained-release preparation |
US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
TR200002059T2 (tr) | 1998-01-16 | 2001-01-22 | Takeda Chemical Industries, Ltd. | Devamlı salınan bileşim, üretim yöntemi ve kullanımı. |
US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
ATE540026T1 (de) | 2008-06-09 | 2012-01-15 | Bristol Myers Squibb Co | Hydroxyphenylsulfonsäureamide als antiapoptotische bcl-inhibitoren |
-
2022
- 2022-11-29 WO PCT/US2022/080565 patent/WO2023102378A1/en active Application Filing
- 2022-11-29 AU AU2022399572A patent/AU2022399572A1/en active Pending
- 2022-11-29 TW TW111145668A patent/TW202327590A/zh unknown
- 2022-11-29 MX MX2024005822A patent/MX2024005822A/es unknown
- 2022-11-29 KR KR1020247021459A patent/KR20240110978A/ko unknown
- 2022-11-29 CA CA3234276A patent/CA3234276A1/en active Pending
- 2022-11-29 IL IL312132A patent/IL312132A/en unknown
-
2023
- 2023-06-05 US US18/329,479 patent/US12018011B2/en active Active
-
2024
- 2024-04-12 US US18/634,587 patent/US20240287023A1/en active Pending
- 2024-05-27 CO CONC2024/0006727A patent/CO2024006727A2/es unknown
- 2024-05-27 DO DO2024000102A patent/DOP2024000102A/es unknown
Also Published As
Publication number | Publication date |
---|---|
IL312132A (en) | 2024-06-01 |
CA3234276A1 (en) | 2023-06-08 |
WO2023102378A1 (en) | 2023-06-08 |
AU2022399572A1 (en) | 2024-05-02 |
DOP2024000102A (es) | 2024-06-30 |
TW202327590A (zh) | 2023-07-16 |
KR20240110978A (ko) | 2024-07-16 |
US12018011B2 (en) | 2024-06-25 |
MX2024005822A (es) | 2024-05-28 |
US20240287023A1 (en) | 2024-08-29 |
US20230322711A1 (en) | 2023-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP20069418A (es) | Compuestos heterocíclicos como inmunomoduladores | |
DOP2022000124A (es) | Derivados de pirazolilo útiles como agentes anticancerígenos | |
CL2021002995A1 (es) | (divisional de solicitud 2922-2020) derivados de tetrahidro-imidazo[4,5-c]piridina como inmunomoduladores de pd-l1. | |
CO2019007863A2 (es) | Derivados de benzooxazol como inmunomoduladores | |
CL2019002204A1 (es) | Compuestos inhibidores del vih. | |
CL2019000221A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1. | |
UY38476A (es) | Inhibidores de arg1 y/o arg2 | |
DOP2021000017A (es) | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos | |
UY37879A (es) | Compuestos de bisamida que activan el sarcómero y sus usos | |
CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
CL2021001753A1 (es) | Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253). | |
BR112020008664A8 (pt) | Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo | |
UY37941A (es) | Derivados de bencimidazol y sus usos | |
CL2020001244A1 (es) | Inhibidores de inmunoproteasoma. | |
CL2021003568A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina (divisional de solicitud n° 202101198) | |
CO2024007129A2 (es) | Inhibidores de lisina acetiltransferasa 6a (kat6a) y usos de los mismos | |
AR128500A1 (es) | Inhibidores de arn helicasa dhx9 y usos de los mismos | |
DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
CL2023002966A1 (es) | Compuestos de oxoisoindolina sustituidos con piridinilo | |
UY37569A (es) | Inhibidores del inmunoproteasoma | |
CO2019013254A2 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
CO2021017202A2 (es) | Compuestos tricíclicos | |
ECSP034494A (es) | Inhibidores novedosos de la farnesil proteino trasferasa como agentes antitumorales | |
AR123281A1 (es) | Compuestos bicíclicos sustituidos útiles como inhibidores de tlr9 | |
ECSP23088732A (es) | Moduladores de trex1 |